Quantum Genomics

EU: ALQGC

€74.4m market cap

€4.24 last close

Quantum Genomics is a biopharmaceutical company developing QGC001, a brain aminopeptidase A inhibitor for the treatment of hypertension and heart failure. Its mechanism is implicated in the 25% of patients resistant to treatment.

Investment summary

Quantum Genomics recently announced a regional licensing agreement for firibastat for the treatment of hypertension in Latin America with Biolab Sanus Pharmaceutical, one of the largest Brazilian pharmaceutical companies, for $21.2m in upfront and milestones as well as royalties. In addition, the company announced the initiation of the pivotal Phase III FRESH study in 500 difficult-to-treat and resistant hypertension patients who are already on treatments from two or three anti-hypertensive classes. Data are expected in H221.

Y/E Dec
Revenue (€m)
EBITDA (€m)
PBT (€m)
EPS (c)
P/E (x)
P/CF (x)
2017A 0.0 (10.3) (10.3) (93.45) N/A N/A
2018A 0.0 (13.6) (13.6) (93.94) N/A N/A
2019E 0.0 (16.5) (17.0) (87.03) N/A N/A
2020E 0.0 (20.7) (22.6) (111.02) N/A N/A
Industry outlook

The angiotensin pathway is one of the primary methods of modulating blood pressure and is the target of many anti-hypertensive drugs, including ACE’s and ARB’s. However, there is a parallel pathway in the brain responsible for the secretion of vasopressin and heart rate that is unaddressed by current drugs and that is being targeted by Quantum Genomics.

Last updated on 20/01/2020
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (€m) 1.2
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 40.9 27.7 (19.7)
Relative* 39.3 18.7 (34.8)
52-week high/low €5.8/€2.9
*% relative to local index
Key management
Jean-Philippe Milon CEO
Marc Karako CFO
Lionel Ségard Founder & Chairman

Content on Quantum Genomics